Evolocumab safety and efficacy in hypercholesterolemia patients with or without diabetes: a retrospective real-world analysis

Evolocumab safety and efficacy in hypercholesterolemia patients with or without diabetes: a retrospective real-world analysis

Abstract Background Proprotein convertase subtilisin/kexin type 9 inhibitors effectively reduce LDL cholesterol and adverse cardiovascular events with a safety profile comparable to a placebo. Limited real-world data exists on their effectiveness in different patient groups. This study evaluated evo...

Full description

Saved in:
Bibliographic Details
Main Authors: Sultan Ibrahim Alraddadi, Hind Almodaimegh, Abdullah Kharbosh, Hadeel Alharbi, Ahmed Ibrahim Fathelrahman, Mona Yaser Alsheikh, Lama Alfehaid
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Diabetology & Metabolic Syndrome
Subjects:
LDL-C
Hypercholesterolemia
Evolocumab
Statin
Ezetimibe
Glycemic control
Online Access:https://doi.org/10.1186/s13098-025-01587-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13098-025-01587-x

Similar Items